(Q40274622)

19 September 2017

title

A review of etoposide in patients with non-small-cell lung cancer (NSCLC). (English)

1 reference

19 September 2017

1 reference

Itri LM

1

1 reference

19 September 2017

Gralla RJ

series ordinal

2

1 reference

19 September 2017

publication date

1 June 1982

1 reference

19 September 2017

published in

Cancer Treatment Reviews

1 reference

19 September 2017

volume

9 Suppl

1 reference

19 September 2017

page(s)

115-118

1 reference

A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980090-X

7 January 2021

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980090-X

7 January 2021

Etoposide (VP-16-213)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980090-X

7 January 2021

Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980090-X

7 January 2021

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980090-X

7 January 2021

Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980090-X

7 January 2021

Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980090-X

7 January 2021

Chemotherapy of small cell carcinoma of the lung with V. P. 16–213

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980090-X

7 January 2021

10.1016/S0305-7372(82)80090-X

Identifiers

DOI

1 reference

19 September 2017

1 reference